Led · Grant · May 2026

LiveEO develops satellite-based monitoring systems and analytics to track risks along linear infrastructure corridors, including pipelines, railways, and power lines. Its Twinspector project is a dual-satellite constellation designed to capture high-resolution and three-dimensional imagery tailored to long, narrow infrastructure routes. The company intends Twinspector data to integrate with its existing analytics platforms to help operators detect threats like unauthorized construction, excavation, and vegetation encroachment earlier. LiveEO is developing the system with European partners and positions the project as part of expanding commercial Earth observation capabilities for infrastructure monitoring. The company’s current disclosed financing activity includes ESA program funding through the InCubed program to support Twinspector’s development.

Participated · Equity · Feb 2025

muffintech develops a pre-trained AI assistant and a specialised LLM focused on the insurance industry to automate tasks like answering customer queries, searching policy details, handling objections, and providing benefit arguments. The platform integrates with internal systems to automate workflows, reduce team workload, and improve conversion and customer satisfaction. Its model is trained on over 30,000 insurance conversations and the company reports its software passed the §34d (34D) exam with a 98% correct rate in an IHK test, outperforming ChatGPT in that evaluation. muffintech already serves brokers, broker pools, and insurance companies. Founded in 2021, the team emphasizes industry-specific expertise and aims to scale its AI capabilities and expand market reach. The company recently raised €3.5 million to support this growth, including €800k from Investitionsbank Berlin’s IBB Pro FIT programme.

Participated · Equity · Mar 2020

mediaire builds AI-powered diagnostic solutions for MRI imaging, including products mdbrain, mdprostate, and mdknee, designed for seamless integration into clinical workflows. Its software provides automated decision support to improve diagnostic accuracy and optimize workflow efficiency. The company reports deployment in over 350 hospitals and clinics across Europe and daily use by radiologists in hundreds of institutions. mediaire says the funding will let it expand its AI portfolio beyond brain, prostate, and knee diagnostics to additional MRI applications. The company highlights partnerships with university hospitals and industry players such as Bayer/Calantic, Sectra, deepc, and radiology chains including Med360, Evidia, Starvision, and RIMED/UNILABS. With a stronger product pipeline and international presence, mediaire is positioning to scale its clinical footprint and commercial reach. mediaire develops mdbrain, an AI- and deep-learning-powered software that performs quantitative MRI analysis to accelerate brain-volume quantification and detect brain lesions. The software integrates into customers' local IT systems, providing an objective second opinion within minutes while emphasizing data protection. mediaire is certified per DIN EN ISO 13485:2016, which enables commercialization of mdbrain in Europe with a CE mark. In December 2020 an international investor pool including High‑Tech Gründerfonds (HTGF), primeCROWD and LIFTT invested approximately €2 million in a seed capital increase to support growth. The company plans European expansion beginning in 2021 (after initial deployments in Germany, Switzerland and Austria in 2020), further international expansion by 2023, and a product portfolio extension into areas such as knee and prostate. Proceeds will be used to scale sales & marketing, build a commercial network, further develop the product range and pursue upselling; headcount is expected to reach about 150 employees by 2025. mediaire builds mdbrain, a software-as-a-service that automates time-consuming radiology tasks and quantifies brain regions from MRI scans to support dementia diagnostics. The product was developed after a radiologist requested automated evaluation of brain regions and a working prototype validated demand in practice. The company charges most customers roughly €10–15 per analysis, with pricing dependent on monthly volume, and offers free trial access plus complimentary installation and service. mediaire positions its solution to reduce quality losses from radiologists’ rising image workloads and extremely short per-image review times. The startup has participated in the Science4Life business-plan competition and employs 16 people. Financially, it has already received funding support as it prepares a Series A round targeted for 2020. mediaire develops a fully automated software solution that delivers precise examination results and diagnostic suggestions within minutes to aid early detection of neurodegenerative diseases such as Alzheimer’s and Multiple Sclerosis. The system uses deep learning methods to detect and evaluate biomarkers, designed to achieve high-quality results with only a limited number of annotated data. The software is fully integrated into the IT system of the radiological practice so patient data never leaves the practice. This integration enables radiologists to provide diagnostic support while the patient is still in the practice. The company was founded in April 2018 and is based in Berlin, Germany. Financially, mediaire raised a six-digit euro funding round backed by High‑Tech Gründerfonds and a group of private investors represented by Sebastian Burian.

Led · Seed · Sep 2019

Belyntic develops Peptide Easy Clean (PEC), a proprietary purification technology that enables parallel peptide purification. PEC relies on an innovative catch-and-release purification between a novel linker molecule and a modified agarose filter material. The technology aims to provide a protocol for actors across the pharmaceutical value chain from research and development to production. Led by Andreas Regnery, Belyntic is a spin-off from the Humboldt-University of Berlin and is based in Berlin, Germany. The company completed a €1.3m seed financing round and plans to use the funds to develop new products and services. It intends to access clinical-stage projects and regulated market segments and to grow internationally.

Led · Debt Financing · Sep 2019

Centrifuge builds a middleware stack for tokenization, covering token issuance, asset management and onchain composability while abstracting institutional-grade technical complexity. Its deRWA framework on Base aims to wrap institutional assets into tokens that can interact with DeFi where legally permitted. A flagship example is deSPXA, a tokenized exposure to an Anemoy S&P 500 fund created with S&P Dow Jones Indices and managed by Janus Henderson. Centrifuge has worked with clients such as Apollo, Janus Henderson and S&P Dow Jones Indices to tokenize complex assets. The company is positioned to help managers, originators, fintechs and DeFi protocols launch vaults without building infrastructure from scratch. As part of the Coinbase strategic investment and Preferred Tokenization Infrastructure designation, Centrifuge seeks to scale distribution and liquidity for tokenized assets while maintaining compliance constraints (noting offerings like deSPXA are limited to non-U.S. eligible investors under Regulation S).